The Immune Assessment of PD-1 Antibody Therapy in Tumor

The Immune Assessment of PD-1 Antibody Therapy in Tumor - A Case-Control Study

This retrospective study will leverage previous immune function monitoring results in conjunction with clinical case data at this medical center.

The primary aim of this study is to evaluate the efficacy and safety of PD(L)-1 antibody therapy for malignant tumors in real-world settings. Treatment outcomes will be assessed according to RECIST V1.1 and iRECIST criteria, with safety graded according to CTCAE V5.0 standards. The study aims to enroll 3000 adult cancer patients treated at this center and analyze their prognosis outcomes based on previous treatment.

Inclusion Criteria:

1. Age ≥18 years.
2. Pathologically confirmed malignant tumors.
3. Complete medical records.
4. Assessable immune function test data.

Exclusion Criteria:

1. Age <18 years.
2. No confirmed tumor pathology.
3. Untraceable medical records.
4. Non-assessable immune function tests.